Compound‐42 alleviates acute kidney injury by targeting RIPK3‐mediated necroptosis

Abstract

Background and PurposeNecroptosis plays an essential role in acute kidney injury and is mediated by receptor‐interacting protein kinase 1 (RIPK1), receptor‐interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain‐like pseudokinase (MLKL). A novel RIPK3 inhibitor, compound 42 (Cpd‐42) alleviates the systemic inflammatory response. The current study was designed to investigate whether Cpd‐42 exhibits protective effects on acute kidney injury and reveal the underlying mechanisms.Experimental ApproachThe effects of Cpd‐42 were determined in vivo through cisplatin‐ and ischaemia/reperfusion (I/R)‐induced acute kidney injury and in vitro through cisplatin‐ and hypoxia/re‐oxygenation (H/R)‐induced cell damage. Transmission electron microscopy and periodic acid–Schiff staining were used to identify renal pathology. Cellular thermal shift assay and RIPK3‐knockout mouse renal tubule epithelial cells were used to explore the relationship between Cpd‐42 and RIPK3. Molecular docking and site‐directed mutagenesis were used to determine the binding site of RIPK3 with Cpd‐42.Key ResultsCpd‐42 reduced human proximal tubule epithelial cell line (HK‐2) cell damage, necroptosis and inflammatory responses in vitro. Furthermore, in vivo, cisplatin‐ and I/R‐induced acute kidney injury was alleviated by Cpd‐42 treatment. Cpd‐42 inhibited necroptosis by interacting with two key hydrogen bonds of RIPK3 at Thr94 and Ser146, which further blocked the phosphorylation of RIPK3 and mitigated acute kidney injury.Conclusion and ImplicationsActing as a novel RIPK3 inhibitor, Cpd‐42 reduced kidney damage, inflammatory response and necroptosis in acute kidney injury by binding to sites Thr94 and Ser146 on RIPK3. Cpd‐42 could be a promising treatment for acute kidney injury.